MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia

Maimaiti, Aikebaier; Abudoukeremu, Kaisaier; Tie, Lu; Pan, Yan; Li, Xuejun

doi:10.1016/j.gene.2015.01.004

Cited by 20 publications

(19 citation statements)

References 44 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, it is also reported to be down-regulated in cancer and prevent metastasis in cancer cells12. Like miR-31, expression of miR-31* is also up-regulated in cancer and two pre-cancer tissues in this study like a report in another study13, but its expression was found to be significantly associated with progression free survival of metastatic colorectal cancer14. MiR-7 is a known OncomiR and its expression was up-regulated in cancer, leukoplakia and lichen planus tissues in this study, like in different cancers from other report15.…”

Section: Discussionsupporting

confidence: 69%

Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: importance in progression of precancer and cancer

Chattopadhyay

Ray

Roy

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Oral cancer generally progresses from precancerous lesions such as leukoplakia (LK), lichen planus (LP) and oral submucous fibrosis (OSMF). Since few of these precancers progress to cancers; it is worth to identify biological molecules that may play important roles in progression. Here, expression deregulation of 7 miRNAs (mir204, mir31, mir31*, mir133a, mir7, mir206 and mir1293) and their possible target genes in 23 cancers, 18 LK, 12 LP, 23 OSMF tissues compared to 20 healthy tissues was determined by qPCR method. Expression of mir7, mir31, mir31* and mir1293 was upregulated and that of mir133a, mir204 and mir206 was downregulated in cancer. Expression of most of these miRNAs was also upregulated in LK and LP tissues but not in OSMF. Expression deregulation of some of the target genes was also determined in cancer, LK and LP tissues. Significant upregulation of mir31 and downregulation of its target gene, CXCL12, in cancer, LK and LP tissues suggest their importance in progression of precancer to cancer. Expression upregulation of mir31 was also validated using GEO data sets. Although sample size is low, novelty of this work lies in studying expression deregulation of miRNAs and target genes in oral cancer and three types of precancerous lesions.

show abstract

Section: Discussionsupporting

confidence: 69%

Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: importance in progression of precancer and cancer

Chattopadhyay

Ray

Roy

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…miRNAs, a group of noncoding RNA molecules composed of 19–25 nucleotides, can posttranscriptionally regulate target gene expression, which results in cell development, differentiation, apoptosis and proliferation 19,20. Besides, miRNAs are also involved in the development of drug resistance by miRNA dysregulation 21.…”

Section: Discussionmentioning

confidence: 99%

Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network

Zheng

Liu

Zheng

et al. 2017

OTT

View full text Add to dashboard Cite

Carfilzomib is a Food and Drug Administration-approved selective proteasome inhibitor for patients with multiple myeloma (MM). However, recent studies indicate that MM cells still develop resistance to carfilzomib, and the molecular mechanisms associated with carfilzomib resistance have not been studied in detail. In this study, to better understand its potential resistant effect and its underlying mechanisms in MM, microarray gene expression profile associated with carfilzomib-resistant KMS-11 and its parental cell line was downloaded from Gene Expression Omnibus database. Raw fluorescent signals were normalized and differently expressed genes were identified using Significance Analysis of Microarrays method. Genetic interaction network was expanded using String, a biomolecular interaction network JAVA platform. Meanwhile, molecular function, biological process and signaling pathway enrichment analysis were performed based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. Totally, 27 upregulated and 36 downregulated genes were identified and a genetic interaction network associated with the resistant effect was expanded basing on String, which consisted of 100 nodes and 249 edges. In addition, signaling pathway enrichment analysis indicated that cytokine–cytokine receptor interaction, autophagy, ErbB signaling pathway, microRNAs in cancer and fatty acid metabolism pathways were aberrant in carfilzomib-resistant KMS-11 cells. Thus, in this study, we demonstrated that carfilzomib potentially conferred drug resistance to KMS-11 cells by cytokine–cytokine receptor interaction, autophagy, ErbB signaling pathway, microRNAs in cancer and fatty acid metabolism pathways, which may provide some potential molecular therapeutic targets for drug combination therapy against carfilzomib resistance.

show abstract

“…These include (but are not limited to) podoplainin [26], deltaNp63 [17], cyclin D1 genotypes [27], specific mRNA expression [28] and DNA methylation [29] profiles, miRNA-31 [30], human telomerase RNA component (hTERC) gene copy number [31], ABCG2 and BMI-1 expression [32], and EGFR protein, mRNA expression and gene copy number gains [33]. Most of these studies, however, consisted of retrospective analyses, including varying (but often limited) number of specimens, without validation on i ndependent datasets.…”

Section: Prognostic Markers Beyond Lohmentioning

confidence: 99%

Prognostic Factors, Predictive Markers and Cancer Biology: The Triad for Successful Oral Cancer Chemoprevention

Novaes

William

2016

Future Oncol.

View full text Add to dashboard Cite

Oral squamous cell carcinomas represent a significant cancer burden worldwide. Unfortunately, chemoprevention strategies investigated to date have failed to produce an agent considered standard of care to prevent oral cancers. Nonetheless, recent advances in clinical trial design may streamline drug development in this setting. In this manuscript, we review some of these improvements, including risk prediction tools based on molecular markers that help select patients most suitable for chemoprevention. We also discuss the opportunities that novel preclinical models and modern molecular profiling techniques will bring to the prevention field in the near future, and propose a clinical trials framework that incorporates molecular prognostic factors, predictive markers and cancer biology as a roadmap to improve chemoprevention strategies for oral cancers. A major global health concern, oral squamous cell carcinoma (OSCC) is currently the 13th most common cancer worldwide, with an estimate of 300,000 new cases, and 145,000 deaths each year [1]. Tobacco, alcohol and/or betel nut exposure are well-established risk factors for OSCC. Interruption of carcinogen use is an obvious key intervention to reduce oral cancer incidence ('primary' prevention). Nonetheless, OSCC risk remains elevated even after alcohol and tobacco cessation and may take up to 20 years to reach baseline levels [2] illustrating the need for development of approaches that can interrupt/reverse the process of carcinogenesis after initiation, but before full malignant transformation. Furthermore, an increase in the incidence of oral cancer in women with no clear etiologic factors has been observed [3], supporting the need for improved understanding of molecular pathways dysregulation that lead to cancer and how they could be targeted for OSSC prevention.Oral potentially malignant lesions (OPMLs) are often clinically characterized as leukoplakia and/or erythroplakia. Histologically, these lesions frequently exhibit hyperplasia, hyperkeratosis and/or varying degrees of dysplasia (i.e., intraepithelial neoplasias [IEN]). OPMLs are not obligate precursors of oral cancers, but they are estimated to precede development of at least 7% of OSCC [4] OPMLs are in and of themselves risk factors for oral cancer, but have a variable frequency of malignant transformation, depending on other clinical, demographic, etiologic, histological and/or molecular features [5]. The anatomic accessibility of OPMLs for examination and biopsies provides an opportunity for clinical and translational studies of oral carcinogenesis. In this review, we will summarize the recent advances and future perspectives of molecularly focused strategies of oral cavity cancers chemoprevention, many of which stem from OPML-based research. We will specifically

show abstract

MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia

Cited by 20 publications

References 44 publications

Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: importance in progression of precancer and cancer

Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: importance in progression of precancer and cancer

Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network

Prognostic Factors, Predictive Markers and Cancer Biology: The Triad for Successful Oral Cancer Chemoprevention

Contact Info

Product

Resources

About